Cancer Research and Treatment

Original Articles

Lymphoma

Increasing Incidence of B-Cell Non-Hodgkin Lymphoma and Occurrence of Second Primary Malignancies in South Korea: 10-Year Follow-up Using the Korean National Health Information Database: Jin Seok Kim, Yanfang Liu, Kyoung Hwa Ha, Hong Qiu, Lee Anne Rothwell, Hyeon Chang Kim; Cancer Res Treat. 2020;52(4):1262-1272. Published online May 4, 2020; DOI: https://doi.org/10.4143/crt.2020.089

Purpose
The epidemiology of B-cell non-Hodgkin lymphoma (BNHL) in Asia is not well described, and rates of second primary malignancies (SPM) in these patients are not known. We aimed to describe temporal changes in BNHL epidemiology and SPM incidence in Korea.
Materials and Methods
A retrospective cohort study used claims data from the National Health Insurance Service that provides universal healthcare coverage in Korea. Newly diagnosed patients aged at least 19 years with a confirmed diagnosis of one of six BNHL subtypes (diffuse large cell B-cell lymphoma [DLBCL], small lymphocytic and chronic lymphocytic [CLL/SLL], follicular lymphoma [FL], mantle cell lymphoma [MCL], marginal zone lymphoma [MZL], and lymphoplasmacytic lymphoma/Waldenström’s macroglobulinemia [WM]) during the period 2006-2015 were enrolled and followed up until death, dis-enrolment, or study end, whichever occurred first. Patients with pre-existing primary cancers prior to the diagnosis of BNHL were excluded.
Results
A total of 19,500 patients with newly diagnosed BNHL were identified out of 27,866 with non-Hodgkin lymphoma (NHL). DLBCL was the most frequently diagnosed subtype (41.9%-48.4% of NHL patients annually, 2011-2015). Standardized incidence of the six subtypes studied per 100,000 population increased from 5.74 in 2011 to 6.96 in 2015, with most increases in DLBCL, FL, and MZL. The incidence (95% confidence interval) of SPM per 100 person-years was 2.74 (2.26-3.29) for CLL/SLL, 2.43 (1.57-3.58) for MCL, 2.41 (2.10-2.76) for MZL, 2.23 (2.07-2.40) for DLBCL, 1.97 (1.61-2.38) for FL, and 1.41 (0.69-2.59) for WM.
Conclusion
BNHL has been increasingly diagnosed in Korea. High rates of SPM highlight the need for continued close monitoring to ensure early diagnosis and treatment.

Citations

Citations to this article as recorded by

Efficacy and safety of netupitant/palonosetron in preventing nausea and vomiting in diffuse large B cell lymphoma patients undergoing R–CHOP chemotherapy
Kunye Kwak, Yong Park, Byung Soo Kim, Ka-Won Kang
Scientific Reports.2024;[Epub] CrossRef
Racial disparities in the incidence and survival outcomes in diffuse large B‐cell lymphoma in adolescents and young adults
Mustafa Wasifuddin, Nosakhare Paul Ilerhunmwuwa, Henry Becerra, Narek Hakobyan, Neharika Shrestha, Ifeanyi Nnamdi Uche, Htet Lin, Hesham Abowali, Jin Zheng, Ruchi Yadav, Akriti Pokhrel, Ladan Enayati, Mitchell Hare, Rohan Hehr, Khrystyna Kozii, Bulat Giba
European Journal of Haematology.2024; 113(4): 454. CrossRef
Causal relationship between beta-2 microglobulin and B-cell malignancies: genome-wide meta-analysis and a bidirectional two-sample Mendelian randomization study
Jiuling Li, Yao Wu, Xin Zhang, Xueju Wang
Frontiers in Immunology.2024;[Epub] CrossRef
Secondary malignancies among mantle cell lymphoma patients
Kossi D. Abalo, Karin E. Smedby, Sara Ekberg, Sandra Eloranta, Simon Pahnke, Alexandra Albertsson-Lindblad, Mats Jerkeman, Ingrid Glimelius
European Journal of Cancer.2023; 195: 113403. CrossRef
Treatment of indolent lymphoma
Seong Hyun Jeong
Blood Research.2022; 57(S1): S120. CrossRef
Upward trend in follicular lymphoma among the Korean population: 10-year experience at a large tertiary institution
Meejeong Kim, Hee Sang Hwang, Hyungwoo Cho, Dok Hyun Yoon, Cheolwon Suh, Chan Sik Park, Heounjeong Go, Jooryung Huh
Journal of Pathology and Translational Medicine.2021; 55(5): 330. CrossRef
Multicenter retrospective analysis of patients with chronic lymphocytic leukemia in Korea
Jun Ho Yi, Gyeong-Won Lee, Ji Hyun Lee, Kwai Han Yoo, Chul Won Jung, Dae Sik Kim, Jeong-Ok Lee, Hyeon Seok Eom, Ja Min Byun, Youngil Koh, Sung Soo Yoon, Jin Seok Kim, Jee Hyun Kong, Ho-Young Yhim, Deok-Hwan Yang, Dok Hyun Yoon, Do Hyoung Lim, Won-Sik Lee,
BLOOD RESEARCH.2021; 56(4): 243. CrossRef

12,526 View
531 Download
18 Web of Science
7 Crossref

Efficacy of Brentuximab Vedotin in Relapsed or Refractory High-CD30–Expressing Non-Hodgkin Lymphomas: Results of a Multicenter, Open-Labeled Phase II Trial: Seok Jin Kim, Dok Hyun Yoon, Jin Seok Kim, Hye Jin Kang, Hye Won Lee, Hyeon-Seok Eom, Jung Yong Hong, Junhun Cho, Young Hyeh Ko, Jooryung Huh, Woo-Ick Yang, Weon Seo Park, Seung-Sook Lee, Cheolwon Suh, Won Seog Kim; Cancer Res Treat. 2020;52(2):374-387. Published online August 13, 2019; DOI: https://doi.org/10.4143/crt.2019.198

Abstract PDF PubReader ePub

Purpose
The treatment outcome of brentuximab vedotin (BV) has not been related with CD30 expression in previous studies enrolling patients with a wide range of CD30 expression level. Thus, this study explored the efficacy of BV in high-CD30–expressing non-Hodgkin lymphoma (NHL) patients most likely to benefit.
Materials and Methods
This phase II study (Clinicaltrials.gov: NCT02280785) enrolled relapsed or refractory high-CD30–expressing NHL, with BV administered intravenously at 1.8 mg/kg every 3 weeks. The primary endpoint was > 40% disease control rate, consisting of complete response (CR), partial response (PR), or stable disease. We defined high CD30 expression as ≥ 30% tumor cells positive for CD30 by immunohistochemistry.
Results
High-CD30-expressing NHL patients (n=33) were enrolled except anaplastic large cell lymphoma. The disease control rate was 48.5% (16/33) including six CR and six PR; six patients (4CR, 2PR) maintained their response over 16 completed cycles. Response to BV and survival were not associated with CD30 expression levels. Over a median of 29.2 months of follow-up, the median progression-free and overall survival rates were 1.9 months and 6.1 months, respectively. The most common adverse events were fever (39%), neutropenia (30%), fatigue (24%), and peripheral sensory neuropathy (27%). In a post-hoc analysis for the association of multiple myeloma oncogene 1 (MUM1) on treatment outcome, MUM1- negative patients showed a higher response (55.6%, 5/9) than MUM1-positive patients (13.3%, 2/15).
Conclusion
BV performance as a single agent was acceptable in terms of disease control rates and toxicity profiles, especially MUM1-negative patients.

Citations

Citations to this article as recorded by

Therapeutic Monoclonal Antibodies for Non-Hodgkin Lymphoma: A Literature Review
Mohammad Sadegh Fallahi, Nasibeh Zerangian, Atousa Ghorbani, Gisou Erabi, Melika Shirali, Elaheh Shabani, Foad Rommasi, Mahsa Mohammadi Najafabadi, Shima Karbasi, Samaneh Toutounchian, Ramin Ahangar-Sirous, Ava Motaghy, Mahsa Heidari, Niloofar Deravi
Current Cancer Therapy Reviews.2024; 20(1): 53. CrossRef
Phase I/II clinical trial of brentuximab vedotin for pretreated Japanese patients with CD30‐positive cutaneous T‐cell lymphoma
Yoji Hirai, Jun Sakurai, Shiho Yoshida, Takashi Kikuchi, Toshiharu Mitsuhashi, Tomoko Miyake, Taku Fujimura, Riichiro Abe, Hiroki Fujikawa, Hikari Boki, Hiraku Suga, Sayaka Shibata, Tomomitsu Miyagaki, Takatoshi Shimauchi, Eiji Kiyohara, Yoshio Kawakami,
The Journal of Dermatology.2024; 51(8): 1037. CrossRef
Brentuximab vedotin therapy followed by autologous peripheral stem cell transplantation as a viable treatment option for an older adult with transformed lymphoma: a case report and literature review
Jiewen Tan, Jinman Zhong, Wanzhen Hu, Guobiao Wu, Chong Zeng, Dan Xiong
Journal of International Medical Research.2024;[Epub] CrossRef
Belantamab mafodotin concentration–QTc relationships in patients with relapsed or refractory multiple myeloma from the DREAMM‐1 and ‐2 studies
Roxanne C. Jewell, Richard J. Mills, Colm Farrell, Sandra A. G. Visser
British Journal of Clinical Pharmacology.2024;[Epub] CrossRef
Resistance mechanisms and potential therapeutic strategies in relapsed or refractory natural killer/T cell lymphoma
Chengji Wang, Liang Wang
Chinese Medical Journal.2024; 137(19): 2308. CrossRef
Treatment of extranodal NK/T-cell lymphoma: From past to future
Zheng Yan, Shuna Yao, Zhizhong Wang, Wenping Zhou, Zhihua Yao, Yanyan Liu
Frontiers in Immunology.2023;[Epub] CrossRef
Rational Targets of Therapy in Extranodal NK/T-Cell Lymphoma
Ajay Major, Pierluigi Porcu, Bradley M. Haverkos
Cancers.2023; 15(5): 1366. CrossRef
Safety of Concurrent Radiation Therapy With Brentuximab Vedotin in the Treatment of Lymphoma
Susan Y. Wu, Penny Q. Fang, Ethan B. Wang, Sairah Ahmed, Madeleine Duvic, Preetesh Jain, Luis E. Malpica Castillo, Ranjit Nair, Raphael E. Steiner, Paolo Strati, Auris O. Huen, Swaminathan P. Iyer, Chelsea C. Pinnix, Bouthaina S. Dabaja, Jillian R. Gunthe
Advances in Radiation Oncology.2023; 8(6): 101279. CrossRef
Novel target and treatment agents for natural killer/T-cell lymphoma
Xiao-Peng Tian, Yi Cao, Jun Cai, Yu-Chen Zhang, Qi-Hua Zou, Jin-Ni Wang, Yu Fang, Jia-Hui Wang, Song-Bin Guo, Qing-Qing Cai
Journal of Hematology & Oncology.2023;[Epub] CrossRef
Treatment‐related adverse events of antibody‐drug conjugates in clinical trials: A systematic review and meta‐analysis
Jinming Li, Guoshuang Shen, Zhen Liu, Yaobang Liu, Miaozhou Wang, Fuxing Zhao, Dengfeng Ren, Qiqi Xie, Zitao Li, Zhilin Liu, Yi Zhao, Fei Ma, Xinlan Liu, Zhengbo Xu, Jiuda Zhao
Cancer Innovation.2023; 2(5): 346. CrossRef
Advances and challenges of immunotherapies in NK/T cell lymphomas
Ling He, Na Chen, Lei Dai, Xingchen Peng
iScience.2023; 26(11): 108192. CrossRef
Brentuximab vedotin in treating Chinese patients with lymphoma: A multicenter, real‐world study
Xudong Zhang, Honghan Qiao, Xiaofei Chai, Xue Gao, Rongjun Ma, Yufu Li, Zunmin Zhu, Mingzhi Zhang
Cancer Medicine.2023; 12(24): 21725. CrossRef
A multi-center and non-interventional registry of brentuximab vedotin in patients with relapsed or refractory CD30-positive lymphoma: the CISL1803/BRAVO study
Seok Jin Kim, Young Rok Do, Ho-Sup Lee, Won-Sik Lee, Jee Hyun Kong, Jae-Yong Kwak, Hyeon-Seok Eom, Joon Ho Moon, Jun Ho Yi, Jeong-Ok Lee, Jae-Cheol Jo, Deok-Hwan Yang
Blood Research.2023; 58(4): 194. CrossRef
Update on Molecular Diagnosis in Extranodal NK/T-Cell Lymphoma and Its Role in the Era of Personalized Medicine
Ka-Hei (Murphy) Sun, Yin-Ting (Heylie) Wong, Ka-Man (Carmen) Cheung, Carmen (Michelle) Yuen, Yun-Tat (Ted) Chan, Wing-Yan (Jennifer) Lai, Chun (David) Chao, Wing-Sum (Katie) Fan, Yuen-Kiu (Karen) Chow, Man-Fai Law, Ho-Chi (Tommy) Tam
Diagnostics.2022; 12(2): 409. CrossRef
Phase 1/dose expansion trial of brentuximab vedotin and lenalidomide in relapsed or refractory diffuse large B-cell lymphoma
Jeffrey P. Ward, Melissa M. Berrien-Elliott, Felicia Gomez, Jingqin Luo, Michelle Becker-Hapak, Amanda F. Cashen, Nina D. Wagner-Johnston, Kami Maddocks, Matthew Mosior, Mark Foster, Kilannin Krysiak, Alina Schmidt, Zachary L. Skidmore, Sweta Desai, Marcu
Blood.2022; 139(13): 1999. CrossRef
Monoclonal Antibodies in the Treatment of Diffuse Large B-Cell Lymphoma: Moving beyond Rituximab
Sotirios G. Papageorgiou, Thomas P. Thomopoulos, Athanasios Liaskas, Theodoros P. Vassilakopoulos
Cancers.2022; 14(8): 1917. CrossRef
Basic immunohistochemistry for lymphoma diagnosis
Junhun Cho
Blood Research.2022; 57(S1): S55. CrossRef
Extranodal Natural Killer/T-Cell Lymphomas: Current Approaches and Future Directions
John C. Reneau, Polina Shindiapina, Zachary Braunstein, Youssef Youssef, Miguel Ruiz, Saira Farid, Walter Hanel, Jonathan E. Brammer
Journal of Clinical Medicine.2022; 11(10): 2699. CrossRef
CD30 + Primary intestinal T-cell lymphoma (unclassified) masquerading as chronic inflammation: a case report
Kashif Osmani, Eshana Shah, Bradley Drumheller, Shaun Webb, Manmeet Singh, Paul Rubinstein, John Patrick Galvin, Megan S. Lim, Carlos Murga-Zamalloa
Diagnostic Pathology.2022;[Epub] CrossRef
EBV-associated NK and T-cell lymphoid neoplasms
Hiroshi Kimura, Laurence de Leval, Qingqing Cai, Won Seog Kim
Current Opinion in Oncology.2022; 34(5): 422. CrossRef
Intravascular NK/T-Cell Lymphoma: What We Know about This Diagnostically Challenging, Aggressive Disease
Magda Zanelli, Paola Parente, Francesca Sanguedolce, Maurizio Zizzo, Andrea Palicelli, Alessandra Bisagni, Illuminato Carosi, Domenico Trombetta, Luca Mastracci, Linda Ricci, Saverio Pancetti, Giovanni Martino, Giuseppe Broggi, Rosario Caltabiano, Alberto
Cancers.2022; 14(21): 5458. CrossRef
Extranodal natural killer/T-cell lymphoma: An overview on pathology and clinical management
Eric Tse, Christopher P. Fox, Alexander Glover, Sang Eun Yoon, Won Seog Kim, Yok-Lam Kwong
Seminars in Hematology.2022; 59(4): 198. CrossRef
Primary Mediastinal B-Cell Lymphoma: Novel Precision Therapies and Future Directions
Huan Chen, Tao Pan, Yizi He, Ruolan Zeng, Yajun Li, Liming Yi, Hui Zang, Siwei Chen, Qintong Duan, Ling Xiao, Hui Zhou
Frontiers in Oncology.2021;[Epub] CrossRef
NK-/T-cell lymphomas
Hua Wang, Bi-bo Fu, Robert Peter Gale, Yang Liang
Leukemia.2021; 35(9): 2460. CrossRef
The landscape of new drugs in extranodal NK/T-cell lymphoma
Liang Wang, Lin-Rong Li, Luo Zhang, Jing-Wen Wang
Cancer Treatment Reviews.2020; 89: 102065. CrossRef
Molecular insights into pathogenesis and targeted therapy of peripheral T cell lymphoma
Caiqin Xie, Xian Li, Hui Zeng, Wenbin Qian
Experimental Hematology & Oncology.2020;[Epub] CrossRef
New agents and regimens for diffuse large B cell lymphoma
Liang Wang, Lin-rong Li, Ken H. Young
Journal of Hematology & Oncology.2020;[Epub] CrossRef
A Phase II Study of Brentuximab Vedotin in Patients with Relapsed or Refractory Epstein-Barr Virus-Positive- and CD30-Positive Lymphomas
Miso Kim, Jeong-Ok Lee, Jiwon Koh, Tae Min Kim, Ji Yun Lee, Yoon Kyung Jeon, Bhumsuk Keam, Dong-Wan Kim, Jong Seok Lee, Dae Seog Heo
SSRN Electronic Journal .2020;[Epub] CrossRef

9,647 View
625 Download
29 Web of Science
28 Crossref

Health-Related Quality of Life in Non-Hodgkin Lymphoma Survivors: A Prospective Cohort Study: Danbee Kang, Juhee Cho, Im Ryung Kim, Mi Kyung Kim, Won Seog Kim, Seok Jin Kim; Cancer Res Treat. 2018;50(4):1051-1063. Published online November 9, 2017; DOI: https://doi.org/10.4143/crt.2017.207

Abstract PDF Supplementary Material PubReader ePub

Purpose
We evaluated health-related quality of life (HRQOL) in long-term survivors of indolent and aggressive non-Hodgkin lymphoma (NHL).
Materials and Methods
TheHRQOLwas assessed by the European Organization for Research and Treatment of Cancer Quality-of-Life Questionnaire Core 30 (EORTC QLQ-C30) at diagnosis in NHL patients between 2008 and 2011, and follow-up evaluation was conducted from June 2014 to February 2015 using EORTC QLQ-C30 and the quality of life in cancer survivors (QOL-CS) questionnaire. We used linear mixed models to compare changes in HRQOL between indolent and aggressive NHL over time.
Results
The HRQOL of long-term survivors with aggressive NHL improved to the similar level of indolent NHL during the follow-up survey. However, survivors of NHL were found to fear the probability of relapse and second malignancy, and the degree of fear was not different between survivors with aggressive stage I/II or III/IV NHL (p > 0.05). Furthermore, a half of survivors reported impaired sense of psychosocial well-being regardless of aggressiveness and stage during follow-up survey. More than 65% of survivors thought they did not receive sufficient support from others, and patients who had financial difficulties at diagnosis were more frequently associated with suffering from insufficient support. Impaired physical and cognitive functioning at diagnosis was significantly associated with lack of life purpose in long-term survivors.
Conclusion
The HRQOL of aggressive NHL survivors improved to a similar level to that of indolent NHL. However, the majority of survivors still had fear of relapse, and psychosocial well-being remained unmet needs.

Citations

Citations to this article as recorded by

Attenuated adiponectin, omentin, increased interleukin-6 and tumor necrosis factor-alpha levels with altered cognition and depression in non-Hodgkin lymphoma patients: A case-control study
Meghavi Kathpalia, Pinki Mishra, Afsha Majid, Mohd. Ashif Khan, Anurag Sharma, Dinesh Bhurani, Nidhi
Journal of Neuroimmunology.2024; 392: 578372. CrossRef
Quality of life and late therapy effects in pediatric non‐Hodgkin lymphoma survivors: Insights from a single‐institution study
Azza Ayad, Reham Khedr, Asmaa Hamoda, Nahla Elnabarawy, Elhamy Rifky, Tamer Diab, Eman El Desouky, Leslie Lehmann, Alaa Elhaddad
Pediatric Blood & Cancer.2024;[Epub] CrossRef
Comparison of tisagenlecleucel with conventional treatments for relapsed/refractory diffuse large B-cell lymphomas: a retrospective external comparator study
Sohee Park, Ju Hwan Kim, Songhee Kim, Jisu Kang, Seoyoung Moon, Seok Jin Kim, Ju-Young Shin
Blood Cancer Journal.2023;[Epub] CrossRef
Factors associated with long-term functional and psychosocial outcomes in patients with non-Hodgkin lymphoma
Bhasker Amatya, Michael Dickinson , Fary Khan
Journal of Rehabilitation Medicine.2023; 55: jrm004816. CrossRef
Experiences of and preferences for self-management among low grade non-Hodgkin's lymphoma survivors: A qualitative interview study
Nickola D. Pallin, Mairead O'Connor, Alannah Gannon, John Browne, Mary R. Cahill, Derville O'Shea
European Journal of Oncology Nursing.2023; 66: 102378. CrossRef
Factors Affecting Health-Related Quality of Life among Survivors of Non-Hodgkin Lymphoma: A Population-Based Study
Stephane Kroudia Wasse, Morgane Mounier, Emerline Assogba, Cédric Rossi, Johan Adnet, Sophie Gauthier, Stephanie Girard, Kueshivi Midodji Atsou, Tienhan Sandrine Dabakuyo-Yonli, Marc Maynadie
Cancers.2023; 15(15): 3885. CrossRef
Lisocabtagene maraleucel for second-line relapsed or refractory large B-cell lymphoma: patient-reported outcomes from the PILOT study
Leo I. Gordon, Fei Fei Liu, Julia Braverman, Daanish Hoda, Nilanjan Ghosh, Mehdi Hamadani, Gerhard C. Hildebrandt, Lily Peng, Shien Guo, Ling Shi, Alison Sehgal
Haematologica.2023; 109(3): 857. CrossRef
Quality of life and fear of cancer recurrence in patients and survivors of non-Hodgkin lymphoma
Susan Ellis, Rhonda F. Brown, Einar B. Thorsteinsson, Kenneth I. Pakenham, Colin Perrott
Psychology, Health & Medicine.2022; 27(8): 1649. CrossRef
Pre‐treatment health‐related quality of life parameters have prognostic impact in patients >65 years with newly diagnosed mantle cell lymphoma: The Nordic Lymphoma Group MCL4 (LENA‐BERIT) experience
Åsa Lindberg, Christian Winther Eskelund, Alexandra Albertsson‐Lindblad, Arne Kolstad, Anna Laurell, Riikka Räty, Kirsten Grønbæk, Christian Hartmann Geisler, Mats Jerkeman
Hematological Oncology.2022; 40(1): 23. CrossRef
Treatment Outcomes and Its Associated Factors Among Adult Patients with Selected Solid Malignancies at Kenyatta National Hospital: A Hospital-Based Prospective Cohort Study
Amsalu Degu, Ermias Mergia Terefe, Eliab Seroney Some, Gobezie T Tegegne
Cancer Management and Research.2022; Volume 14: 1525. CrossRef
Living with or beyond lymphoma: A rapid review of the unmet needs of lymphoma survivors
Vanessa Boland, Amanda Drury, Greg Sheaf, Anne‐Marie Brady
Psycho-Oncology.2022; 31(7): 1076. CrossRef
The forgotten survivor: A comprehensive review on Non‐Hodgkin lymphoma survivorship
Mohamad S. Alabdaljabar, Urshila Durani, Carrie A. Thompson, Louis S. Constine, Shahrukh K. Hashmi
American Journal of Hematology.2022; 97(12): 1627. CrossRef
Unmet Needs and Quality of Life of Colorectal Cancer Survivors Immediately after Treatment Ends and 5 Years
Hyedan Kim, Eunsook Wi, Mi Hwa Jang, Sung Hee Jo, Hye Kyung Kim
Asian Oncology Nursing.2022; 22(3): 145. CrossRef
Trajectories of symptom severity predicts quality of life change in newly diagnosis lymphoma survivors: An initial study
Chih‐Jung Wu, Yu‐Chi Chen, Li‐Yuan Bai, Tzeon‐Jye Chiou, Kuan‐Chia Lin, Ya‐Jung Wang
European Journal of Cancer Care.2022;[Epub] CrossRef
Exploring health-related quality of life among non-Hodgkin’s lymphoma survivors after completion of primary treatment: a cross-sectional study in Thailand
Pichitra Lekdamrongkul, Kanaungnit Pongthavornkamol, Alex Molassiotis, Aurawamon Sriyuktasuth, Noppadol Siritanaratkul, Natkamol Chansatitporn
Supportive Care in Cancer.2021; 29(11): 6511. CrossRef
Experiences of patients with lung cancer receiving concurrent chemo-radiotherapy
Choi Eunsook, Park Sunhee
Clinical Journal of Nursing Care and Practice.2021; 5(1): 015. CrossRef
Coping strategies among patients with malignant lymphoma– a qualitative study from the perspectives of Swedish patients
Stinne Glasdam, Charlotta Bjerström, Cecilia Engberg de Carvalho
European Journal of Oncology Nursing.2020; 44: 101693. CrossRef
Impact of fear of cancer recurrence on survival among lymphoma patients
Seok Jin Kim, Danbee Kang, Im Ryung Kim, Sang Eun Yoon, Won Seog Kim, Phyllis N. Butow, Eliseo Guallar, Juhee Cho
Psycho-Oncology.2020; 29(2): 364. CrossRef
Health-related quality of life in the phase III GALLIUM study of obinutuzumab- or rituximab-based chemotherapy in patients with previously untreated advanced follicular lymphoma
Andrew Davies, Peter Trask, Judit Demeter, Axel Florschütz, Mathias Hänel, Tomohiro Kinoshita, Ruth Pettengell, Hang Quach, Stephen Robinson, Shalal Sadullah, Juan-Manuel Sancho, Miklos Udvardy, Mathias Witzens-Harig, Andrea Knapp, Wenxin Liu
Annals of Hematology.2020; 99(12): 2837. CrossRef
Quality of Life and Impact of Cancer: Differences in Rural and Nonrural Non‐Hodgkin's Lymphoma Survivors
Devon Noonan, Matthew LeBlanc, Cherie Conley, Habtamu Benecha, Ashley Leak‐Bryant, Kellen Peter, Sheryl Zimmerman, Deborah Mayer, Sophia Smith
The Journal of Rural Health.2020; 36(4): 536. CrossRef
Semen quality in non-Hodgkin lymphoma survivors: a monocentric retrospective study
Francesco Pallotti, Marianna Pelloni, Fabiana Faja, Silvia Di Chiano, Alice Di Rocco, Andrea Lenzi, Francesco Lombardo, Donatella Paoli
Human Reproduction.2020;[Epub] CrossRef
Prognostic Value of Post-diagnosis Health-Related Quality of Life for Overall Survival in Breast Cancer: Findings from a 10-Year Prospective Cohort in Korea
Tran Thi Xuan Mai, Jin Hyuk Choi, Myung Kyung Lee, Yoon Jung Chang, So-Youn Jung, Hyunsoon Cho, Eun Sook Lee
Cancer Research and Treatment.2019; 51(4): 1600. CrossRef

16,915 View
425 Download
21 Web of Science
22 Crossref

Case Reports

A Rare Presentation of Follicular Lymphoma: Cerebellar Involvement, Successfully Treated with a Combination of Radiotherapy and Chemotherapy: Nuri Karadurmus, Selmin Ataergin, Gokhan Erdem, Mustafa Cakar, Ozdes Emer, Sukru Ozaydin, Mustafa Ozturk, Mukerrem Safali, Fikret Arpaci; Cancer Res Treat. 2013;45(3):234-238. Published online September 30, 2013; DOI: https://doi.org/10.4143/crt.2013.45.3.234

Abstract PDF PubReader ePub

The central nervous system (CNS) is an important area of involvement for both high-grade, aggressive primary and secondary lymphomas. Although follicular lymphoma represents a low-grade histology, it may rarely present with CNS involvement. Here, we describe a patient diagnosed with follicular lymphoma who was presented with cerebellar involvement.

Citations

Citations to this article as recorded by

Follicular lymphoma with secondary central nervous system relapse: a case report and literature review
Yuri Tsuboi, Misayo Shimizu, Akihiro Kuroda, Takuya Suyama, Masanori Seki, Atsushi Shinagawa
Oxford Medical Case Reports.2023;[Epub] CrossRef
Rare central nervous system lymphomas
Furqaan Ahmed Kaji, Nicolás Martinez‐Calle, Vishakha Sovani, Christopher Paul Fox
British Journal of Haematology.2022; 197(6): 662. CrossRef
Secondary parenchymal CNS involvement by lymphoma including rare types: Follicular and EBV-positive NK/T cell lymphoma, nasal type
B.K. Kleinschmidt-DeMasters, Ahmed Gilani
Annals of Diagnostic Pathology.2021; 53: 151765. CrossRef
Cerebral Amyloidoma Resulting from Central Nervous System Lymphoplasmacytic Lymphoma: A Case Report and Literature Review
Geetha Jagannathan, Guldeep Uppal, Kevin Judy, Mark T. Curtis
Case Reports in Pathology.2018; 2018: 1. CrossRef
Sites of extranodal involvement are prognostic in patients with stage 1 follicular lymphoma
Aditi Shastri, Murali Janakiram, Ioannis Mantzaris, Yiting Yu, Jaime S. Londono, Amit K. Verma, Stefan K. Barta
Oncotarget.2017; 8(45): 78410. CrossRef
Follicular Lymphoma Presenting with Leptomeningeal Disease
Rubens Costa, Ricardo Costa, Renata Costa
Case Reports in Hematology.2014; 2014: 1. CrossRef

11,804 View
96 Download
6 Crossref

F-18 FDG PET-positive Fibrous Dysplasia in a Patient with Intestinal Non-Hodgkin's Lymphoma: Mi Kim, Hyeong Su Kim, Jung Han Kim, Joo Hyun Jang, Kook Jin Chung, Mi Kyung Shin, Hee Sung Hwang, Byung Chun Kim, So Young Jung; Cancer Res Treat. 2009;41(3):171-174. Published online September 28, 2009; DOI: https://doi.org/10.4143/crt.2009.41.3.171

Abstract PDF PubReader ePub

Fibrous dysplasia (FD) is a common benign bone disorder of an unclear etiology. It is known that FD can appear without an increased FDG uptake on F-18 fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT). However, there are also several reports that FD showed increased FDG uptake and this mimicked malignant bone involvement on FDG-PET. Herein we describe a case of biopsy-proven FDG-PET positive FD in a patient with intestinal non-Hodgkin's lymphoma (NHL). A 45-year-old woman was diagnosed with intestinal NHL, which was removed by right hemicolectomy. After the operation, the FDG-PET/CT scan showed hypermetabolic activity in the right transverse process of the T10 vertebra. The patient then received a total of 6 cycles of R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone) chemotherapy every 3 weeks. After completion of the planned chemotherapy, the 2^nd FDG-PET/CT showed increased FDG uptake (SUVmax=6.0 g/mL) of the previous bone lesion. The MR images revealed a T1-hypointense lesion with sharp borders in the same region, and this showed homogenous contrast enhancement on the fat-suppressed T1-weighted images. After the radiologic studies were carefully reviewed, the bone lesion was assumed to be benign such as FD. We performed bone biopsy and the histological examination confirmed the diagnosis of FD. In conclusion, bone lesions with FDG uptake need to be carefully interpreted when evaluating patients with known malignancy.

Citations

Citations to this article as recorded by

Polyostotic Fibrous Dysplasia Mimicking Bone Involvement in Hodgkin Lymphoma: A Pediatric Case and Literature Review
Gianfranco Lapietra, Maria Luisa Moleti, Fiorina Giona, Arianna Turchetti, Mauro Celli, Alessandro Corsi, Anna Zambrano, Miriam D'Avanzo, Luca Celli, Anna Maria Testi
Acta Haematologica.2021; 144(2): 212. CrossRef
PET/CT and PET/MRI in ophthalmic oncology (Review)
Maria Kalemaki, Apostolos Karantanas, Dimitris Exarchos, Efstathios Detorakis, Odysseas Zoras, Kostas Marias, Corina Millo, Ulas Bagci, Ioannis Pallikaris, Andreas Stratis, Ioannis Karatzanis, Kostas Perisinakis, Pavlos Koutentakis, Georgios Kontadakis, D
International Journal of Oncology.2020;[Epub] CrossRef
Extensive polyostotic fibrous dysplasia evaluated for malignant transformation with99mTc-MDP bone scan and18F-FDG PET/CT
William Makis, Stephan Probst
BJR|case reports.2016; 2(3): 20150440. CrossRef
FDG Uptake in Liposclerosing Myxofibrous Tumor Causes Upstaging of Hodgkin Lymphoma
Jongho Kim, Wengen Chen, Charles Resnik, Vasken Dilsizian, Qing Chen, Amy S. Kimball
Clinical Nuclear Medicine.2015; 40(4): 325. CrossRef
Fibrous dysplasia mimicking vertebral bone metastasis on 18F-FDG PET/computed tomography in a patient with tongue cancer
Ibrahim Guler, Alaaddin Nayman, Gonca Kara Gedik, Mustafa Koplay, Oktay Sari
The Spine Journal.2015; 15(6): 1501. CrossRef
Fibrous Dysplasia Mimicking Bone Metastasis on Both Bone Scintigraphy and 18F-FDG PET-CT: Diagnostic Dilemma in a Patient with Breast Cancer
Sudhir Suman KC, Punit Sharma, Harmandeep Singh, Chandrasekhar Bal, Rakesh Kumar
Nuclear Medicine and Molecular Imaging.2012; 46(4): 318. CrossRef

9,152 View
46 Download
6 Crossref

First
Prev
Page of 1
Next
Last

Search